Biology of bone metastases: Causes and consequences

Clinical Breast Cancer

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Harvey, Harold A ^a   Von Reyn Cream, Leah ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Denosumab; Osteoclasts; RANK; Skeletal complications

Indexed keywords

ALKALINE PHOSPHATASE; ANASTROZOLE; BONE CEMENT; CALCIUM; CLODRONIC ACID; DENOSUMAB; ENDOTHELIN RECEPTOR ANTAGONIST; IBANDRONIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; SAMARIUM; STRONTIUM 90; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANGIOGENESIS; BIOLOGY; BONE DEVELOPMENT; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; FRACTURE; HUMAN; HYPERCALCEMIA; KYPHOPLASTY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSYNTHESIS; PERCUTANEOUS VERTEBROPLASTY; PROSTATE CANCER; RADIODIAGNOSIS; REVIEW; SKELETON; SPINAL CORD COMPRESSION; TUMOR CELL;

EID: 34548262727     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.001     Document Type: Article

References (52)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-176.
2. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol 2005; 6:161-171.
3. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67:390-396.
4. Hillner BE. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 2001; 28(4 suppl 11):64-68.
5. Smid M, Wang Y, Jan GM, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24:2261-2267.
6. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
7. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
8. Roodman DG. Mechanisms of bone matastases. N Engl J Med 2004; 350:1655-1664.
9. Guise TA, Kozlow WM, Heras-Herzig A, et al. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005; 5(suppl 2):S46-S53.
10. Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005; 65:11001-11009.
11. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10:169-180.
12. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003; 415(suppl):S32-S38.
13. Mundy G. Preclinical models of bone metastases. Semin Oncol 2001; 28(4 suppl 11):2-8.
14. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004; 4:308-318.
15. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107:1235-1244.
16. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res 2003; 415(suppl):S67-S74.
17. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
18. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
19. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, duoble-blind, multicenter comparative trial. Cancer 2003; 98:1735-1744.
20. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
21. Lipton A, Small E, Saad F, et al. The new bishosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(suppl 2):45-54.
22. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
23. Sabino MA, Mantyh PW. Pathophysiology of bone pain. J Support Oncol 2005; 3:15-24.
24. Harvey HA. The management of hypercalcemia of malignancy. Support Care Cancer 1995; 3:123-129.
25. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 2002; 7:481-491.
26. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61-66.
27. Lipton A, Colombo-Berra A, Bukowski RM, et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004; 10:S6397-S6403.
28. Hei YJ. Fractures negatively affect survival in patients with bone metastases from breast cancer. Breast Cancer Res Treat 2005; 94:260 (Abstract #6036).
29. Hamaoka T, Madwell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953.
30. Lipton A. Biochemical bone markers in breast cancer. Cancer Treat Rev 2006; 32:20-22.
31. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal 1 metastases. Clin Orthop Relat Res 2003; 415:S138-S147.
32. Coleman RE, Major P, Lipton A. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
33. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasis- a systemic review. Radiother Oncol 2005; 75:258-270.
34. Manabe J, Kawaguchi N, Matsumoto S. Surgical treatment of bone metastasis: indications and outcomes. Int J Clin Oncol 2005; 10:103-111.
35. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.
36. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 2001; 296:235-242.
37. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
38. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14:1399-1405.
39. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-4057.
40. Body JJ, Facon T, Coleman RE, et al. A study of the biologic receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-1228.
41. Lipton A. Phase II trial of denosumab in breast cancer with bone metastases. J Clin Oncol 2006; 24(18 suppl):6S (Abstract #512).
42. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17.
43. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
44. Powles T, Paterson A, McCloskey E. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006; 8:13.
45. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. ATAC Trialists' Group. J Bone Miner Res 2006; 21:1215-1223.
46. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
47. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
48. Smith MR. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology 2004; 18:21-25.
49. Ryan CW, Huo D, Demers L, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176:972-978.
50. Gnant M. Management of bone loss induced by aromatase inhibitors. Cancer Inv 2006; 24:328-330.
51. Brufsky A. Management of cancer treatment induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006; 33:S13-S17.
52. Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol 2004; 31(6 suppl 12):23-30.